WO2007081901A2 - Derives de pyrimidinone comme inhibiteurs de proteines kinases - Google Patents

Derives de pyrimidinone comme inhibiteurs de proteines kinases Download PDF

Info

Publication number
WO2007081901A2
WO2007081901A2 PCT/US2007/000441 US2007000441W WO2007081901A2 WO 2007081901 A2 WO2007081901 A2 WO 2007081901A2 US 2007000441 W US2007000441 W US 2007000441W WO 2007081901 A2 WO2007081901 A2 WO 2007081901A2
Authority
WO
WIPO (PCT)
Prior art keywords
mmol
compound according
following structure
methyl
oxo
Prior art date
Application number
PCT/US2007/000441
Other languages
English (en)
Other versions
WO2007081901A3 (fr
Inventor
Congxin Liang
Marcel Koenig
Original Assignee
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Scripps Research Institute filed Critical The Scripps Research Institute
Publication of WO2007081901A2 publication Critical patent/WO2007081901A2/fr
Publication of WO2007081901A3 publication Critical patent/WO2007081901A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés de pyrimidinone qui possèdent de façon inattendue des propriétés thérapeutiques accrues d'inhibiteurs de protéines kinases et sont utiles pour traiter des troubles liés à des activités anormales de protéines kinases telles que des maladies inflammatoires et certains types de cancer.
PCT/US2007/000441 2006-01-05 2007-01-05 Derives de pyrimidinone comme inhibiteurs de proteines kinases WO2007081901A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75695006P 2006-01-05 2006-01-05
US60/756,950 2006-01-05

Publications (2)

Publication Number Publication Date
WO2007081901A2 true WO2007081901A2 (fr) 2007-07-19
WO2007081901A3 WO2007081901A3 (fr) 2008-01-03

Family

ID=38256967

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/000441 WO2007081901A2 (fr) 2006-01-05 2007-01-05 Derives de pyrimidinone comme inhibiteurs de proteines kinases

Country Status (1)

Country Link
WO (1) WO2007081901A2 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166857A1 (fr) * 2007-06-06 2010-03-31 Xcovery, INC. Composés d'inhibiteur de kinase
US8507499B2 (en) 2010-12-06 2013-08-13 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
US8563558B2 (en) 2010-12-06 2013-10-22 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
US9056110B2 (en) 2011-12-06 2015-06-16 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
US9115089B2 (en) 2013-06-07 2015-08-25 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US9365546B2 (en) 2010-12-06 2016-06-14 Confluence Life Sciences Inc. Substituted pyridinone-pyridinyl compounds
US11844801B2 (en) 2020-03-27 2023-12-19 Aclaris Therapeutics, Inc. Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087677A2 (fr) * 2003-04-03 2004-10-14 Pharmacia Corporation Pyrimidinones substituees

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087677A2 (fr) * 2003-04-03 2004-10-14 Pharmacia Corporation Pyrimidinones substituees

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2166857A1 (fr) * 2007-06-06 2010-03-31 Xcovery, INC. Composés d'inhibiteur de kinase
CN101827525A (zh) * 2007-06-06 2010-09-08 蒂罗格内克斯公司 激酶抑制剂化合物
EP2166857A4 (fr) * 2007-06-06 2011-03-30 Xcovery Inc Composés d'inhibiteur de kinase
US8198276B2 (en) 2007-06-06 2012-06-12 Xcovery Holding Company Llc Kinase inhibitor compounds
US9365546B2 (en) 2010-12-06 2016-06-14 Confluence Life Sciences Inc. Substituted pyridinone-pyridinyl compounds
US8563558B2 (en) 2010-12-06 2013-10-22 Confluence Life Sciences, Inc. Substituted pyridine urea compounds
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US8507499B2 (en) 2010-12-06 2013-08-13 Confluence Life Sciences, Inc. Substituted indole/indazole-pyrimidinyl compounds
US9365547B2 (en) 2010-12-06 2016-06-14 Confluence Life Sciences Inc. Substituted pyridinone-pyridinyl compounds
EP3469907A1 (fr) 2010-12-06 2019-04-17 Aclaris Therapeutics, Inc. Composés pyridinone-pyridinyl substitués
US9056110B2 (en) 2011-12-06 2015-06-16 Confluence Life Sciences, Inc. Substituted pyrimidinone-phenyl-pyrimidinyl compounds
US9115089B2 (en) 2013-06-07 2015-08-25 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US9636333B2 (en) 2013-06-07 2017-05-02 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
EP3845529A1 (fr) 2013-06-07 2021-07-07 Aclaris Therapeutics, Inc. Composés de pyridinone-pyridinyle substitués avec méthyle/fluoro-pyridinyle-méthoxy et des composés de pyridinone-pyridinyle substitués avec fluoro-pyrimidinyl-méthoxy
US11844801B2 (en) 2020-03-27 2023-12-19 Aclaris Therapeutics, Inc. Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

Also Published As

Publication number Publication date
WO2007081901A3 (fr) 2008-01-03

Similar Documents

Publication Publication Date Title
WO2007081901A2 (fr) Derives de pyrimidinone comme inhibiteurs de proteines kinases
JP2020011971A (ja) ガンの治療方法
EP1453516A2 (fr) Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament
KR101414778B1 (ko) 페닐피리미돈을 함유하는 화합물, 그 약물 조성물 및 그 제조방법과 용도
CZ20032233A3 (cs) Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
AU2016248056B2 (en) Crystalline FGFR4 inhibitor compound and uses thereof
CA2689607A1 (fr) Composes d'inhibiteur de kinase
CN107406428B (zh) Fyn激酶抑制剂
JPWO2005080392A1 (ja) ピラゾロキノロン誘導体およびその用途
KR100696139B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체 및그의 제조방법
CN115353508B (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
NZ338006A (en) Aminopyrimidine derivatives, their preparation, and pharmaceutical compositions thereof; useful for inhibiting nitric oxide synthase activity
WO2020125759A1 (fr) Composé en tant qu'inhibiteur de la voie de signalisation wnt et son utilisation médicale
JP2021513530A (ja) テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用
CN111057021B (zh) 均三嗪类化合物及其制备方法和用途
WO2019100743A1 (fr) Inhibiteur ciblant à la fois la parp-1 et la pi3k comprenant un benzofurane
CN114539267A (zh) 一种吴茱萸碱衍生物及其应用
WO2016107541A1 (fr) Composé de pyrrole-amide, son procédé de préparation et son utilisation
CN111960970B (zh) 抗肿瘤化合物
EP3632912B1 (fr) Inhibiteurs de protéine kinase
DK2683719T3 (en) SUBSTITUTED [(5H-pyrrolo [2,1-c] [1,4] benzodiazepin-11-yl) -piperazin-1-yl] -2,2-DIMETHYLPROPANSYREFORBINDELSER as double acting H1-inverse agonists / 5-HT 2A antagonists
CA2882438A1 (fr) Procedes et intermediaires pour la preparation de dasatinib
Mohamed et al. Synthesis and Evaluation of The Antiviral Activity of Novel 2-Thiopyrimidine-5-Carbonitrile Derivatives
NL2029098B1 (en) Substituted thiophene compounds as D-dopachrome tautomerase inhibitors
CN115073467B (zh) 一种嘧啶并咪唑类化合物及其药用组合物和应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07717806

Country of ref document: EP

Kind code of ref document: A2